bi-specific IgG antibodies (Merus/Selexis)

N/A

Report date: 2025/03/14 16:36:26

Base Information

Drug Namebi-specific IgG antibodies (Merus/Selexis)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionNerve growth factor receptor Trk-A inhibitors

TargetsNerve growth factor receptor Trk-A

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsSwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMerus Nv

China Registration ClassN/A

Develop Information

Active CompaniesMerus Nv Selexis SA

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A